
Primary care clinics in underserved areas including eye disease detection programs could reduce vision loss in the US.

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.
She has a BA in English language and literature from Rutgers University. You can connect with Julia on LinkedIn.

Primary care clinics in underserved areas including eye disease detection programs could reduce vision loss in the US.

Disparities in hypertension brought on by neighborhood deprivation were most prominently found in Black patients.

The new guidelines are another method of keeping a high-quality standard for colorectal cancer screening.

A federal judge determined that all people being actively treated for HIV can enlist in the military.

Cancer detection was slower to rebound after the COVID-19 pandemic compared with endoscopic activity, specifically in gastric cancers such as colorectal cancer.

Many patients could be at risk of colorectal cancer (CRC) without realizing as most patients don’t know if their immediate family has had CRC.

Patients with non-small cell lung cancer (NSCLC) can use lazertinib in combination with amivantamab as a first-line treatment.

Although the FDA approval of Guardant Health’s Shield blood test provides an appealing alternative to other colorectal cancer screening methods, the advantages and disadvantages should be highlighted with patients.

Patients with symptoms of gastrointestinal (GI) problems and survivors of colon cancer were more likely to use oncology specialty care.

A high number of adverse events were reported in a late-stage trial conducted by Merck for treatment in lung cancer.

Relapsed or refractory cutaneous t-cell lymphoma can be treated in adults with the new FDA approval of denileukin diftitox immunotherapy.

New data from the National Vital Statistics System show differences in mortality rates based on sex, race, and comorbidities in the United States.

Jessilin Quint of Smart Eye Care and Rebecca Petris of Dry Eye Foundation talk about how health care and eye care professionals can educate and identify patients with dry eye.

A simple, user-friendly decision-making model that used self-reported information was able to perform well in outpatient decision-making for patients with colorectal cancer (CRC).

Patients with colorectal liver metastases had local tumor progression when they had minimal ablative margin from intraprocedural contrast-enhanced computed tomography.

New therapies to treat EGFR-mutated non–small cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitors (TKIs) are needed to address EGFR TKI resistance after osimertinib.

Tumor location, tumor size, and T stage associated with patients with rectal cancer who have inferior mesenteric artery lymph node metastases.

A new study has found that prior authorizations for anti–vascular endothelial growth factor treatment led to a delay in patient care for most patients.

Test your knowledge of the July 2024 issue of AJMC with this quick quiz!

Mina Massaro-Giordano, MD, discusses how raising awareness about dry eye can help patients avoid worsening the condition.

The Shield blood test developed by Guardant has been approved by the FDA as a primary screening option for colorectal cancer, providing a more convenient method of screening.

Doug Fulling, MA, and Andrew Cournoyer of Precision AQ discussed what payers can contribute to discussions around drug pricing during clinical development.

Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.

A late-breaking abstract focused on a head-to-head comparison between dolutegravir/lamivudine (DTG/3TC) and bictegravir/emtricitabine/tenofovir (BIC/FTC/TAF) in the treatment of HIV.

Patients diagnoesd with metabolic dysfunction–associated steatotic liver disease may have a higher risk of colorectal cancer (CRC) or colorectal adenoma.

Doug Fulling, MA, and Andrew Cournoyer, MBA, discuss how patients could benefit from payers learning more about a new drug by joining clinical trials earlier.

Andrew Cournoyer discusses how introducing payers into clinical trials earlier could help make the introduction of new technologies into the space more efficient and less time-consuming.

Jessilin Quint, OD, MBA, FAAO, and Rebecca Petris discussed the different presentations of dry eye and how patients can address their symptoms with their doctors.

The Society for Pediatric Dermatology (SPD) Annual Meeting focused on different aspects of pediatric dermatology, including topical treatments, technology, and misinformation.

Introducing payers into clinical trials earlier could help to shape the value of a drug, according to Andrew Cournoyer of Precision AQ.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
